Market Overview

UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Boston Scientific Corporation

Share:
Related BSX
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2
Opinion: Here Are 10 Trends (And 11 Investments) To Watch In 2015

In a report published Wednesday, Citigroup reiterated its Buy rating on Boston Scientific Corporation (NYSE: BSX), and slightly raised its price target from $7.30 to $8.20.

Citigroup noted, “BSX's shares have moved up significantly faster than we expected since last Thanksgiving, but we still see room for the stock on a fundamental basis as trends are improving and the peer group valuation has moved up. Plus, we still believe the call option on Durata being removed from the market is largely underappreciated.”

Boston Scientific Corporation closed on Tuesday at $7.10.

Latest Ratings for BSX

DateFirmActionFromTo
Jan 2015Leerink SwannUpgradesMarket PerformOutperform
Oct 2014Goldman SachsUpgradesSellNeutral
Oct 2014BenchmarkUpgradesHoldBuy

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (BSX)

Around the Web, We're Loving...

Get Benzinga's Newsletters